<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937611</url>
  </required_header>
  <id_info>
    <org_study_id>20121A021007</org_study_id>
    <nct_id>NCT01937611</nct_id>
  </id_info>
  <brief_title>Intramuscular Dexmedetomidine as Premedication</brief_title>
  <official_title>Comparison of Dexmedetomidine and Midazolam as Intramuscular Premedication for Suspension Laryngoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou First People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many studies have been conducted for the feasibility of using dexmedetomidine as
      premedication. However, bradycardia and hypotension frequently occurred following the
      premedication with dexmedetomidine, either via intramuscular or intravenous route. This is
      particularly true when using a high dose of dexmedetomidine: a intramuscular dose over 2
      μg•kg-1 or a intravenous dose over 1 μg•kg-1 can elicit marked decreases in heart rate and
      mean arterial blood pressure. Subsequent studies using high-dose dexmedetomidine further
      revealed the potential impact of its detrimental haemodynamic profile on clinical outcomes.
      Most studies using high-dose dexmedetomidine were predominantly adopted with the dose-finding
      study performed by Aho and colleague, whom reported that 2.5 μg•kg-1 dose of intramuscular
      dexmedetomidine was comparably sedative and anxiolytic to 0.08 mg•kg-1 midazolam. However,
      few investigations have addressed the clinical effects of low-dose dexmedetomidine as
      premedication. Considering modern anaesthesia has advanced a long way towards eliminating the
      routine need for a deep preoperative sedation. It has, therefore, become desirable to asses
      dexmedetomidine as an effective premedication using a moderate sedative dose to minimize its
      undesired hemodynamic effects. We set a prospective study to compare the sedative,
      haemodynamic, adjuvant anaesthetic effects and patient's satisfaction of low-dose
      dexmedetomidine (1μg•kg-1) with midazolam (0.03 mg•kg-1), the most commonly used
      premedication, used as an intramuscular injective administration in patients undergoing
      suspension laryngoscopic surgery under general anaesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative heart rate response</measure>
    <time_frame>Participants will be monitored for the duration of anesthesia and recovery, an expected average of 2 hours.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation</measure>
    <time_frame>Participants will be monitored for the duration of anesthesia and recovery, an expected average of 2 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjuvant anesthesia effect</measure>
    <time_frame>Participants will be monitored for the duration of anesthesia, an expected average of half an hour.</time_frame>
    <description>Target-controlled infusion concentrations of propofol and remifentanyl at intubation, start and completion of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's over-all satisfaction</measure>
    <time_frame>On leaving the post-care unite, an expected average of 2 min.</time_frame>
    <description>On discharge from recovery patients were asked to rate their satisfaction with the anaesthesia and the surgery that they had received as; highly satisfactory, acceptable, or unacceptable.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean arterial blood pressure</measure>
    <time_frame>Participants will be monitored for the duration of anesthesia and recovery, an expected average of 2 hours.</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Laryngoscopy</condition>
  <condition>Preanesthetic Medication</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexmedetomidine 1μg•kg-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>midazolam 0.03 mg•kg-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam</description>
    <arm_group_label>midazolam</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients aged 18-55 years old, American Society of Anaesthesiologists physical
             status I, scheduled for elective suspension laryngoscopic surgery of benign vocal fold
             lesions.

        Exclusion Criteria:

          -  Patients with neurological deficits

          -  Pregnancy

          -  Imprisonment

          -  Morbid obesity (body mass index ≥ 30 kg•m−2)

          -  Preoperative heart rate &lt;45 beats•min−1

          -  Second or third degree atrioventricular block

          -  Antihypertensive medication with α-methyldopa, clonidine or other α2-adrenergic
             agonist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiangcai Ruan, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated First People's Hospital of Guangzhou, Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiangcai Ruan, MD, PhD.</last_name>
    <phone>+8620-81048306</phone>
    <email>xc_ruan@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huan Yang, MD.</last_name>
    <phone>+8620-81048310</phone>
    <email>yanghuan0401@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated First People's Hospital of Guangzhou, Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinhong Wang, Bs</last_name>
      <phone>+8620-81048178</phone>
      <email>gzhosp@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Jayaraman L, Sinha A, Punhani D. A comparative study to evaluate the effect of intranasal dexmedetomidine versus oral alprazolam as a premedication agent in morbidly obese patients undergoing bariatric surgery. J Anaesthesiol Clin Pharmacol. 2013 Apr;29(2):179-82. doi: 10.4103/0970-9185.111680.</citation>
    <PMID>23878437</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta K, Jain M, Gupta PK, Rastogi B, Saxena SK, Manngo A. Dexmedetomidine premedication for fiberoptic intubation in patients of temporomandibular joint ankylosis: A randomized clinical trial. Saudi J Anaesth. 2012 Jul;6(3):219-23. doi: 10.4103/1658-354X.101211.</citation>
    <PMID>23162393</PMID>
  </results_reference>
  <results_reference>
    <citation>Mowafi HA, Aldossary N, Ismail SA, Alqahtani J. Effect of dexmedetomidine premedication on the intraocular pressure changes after succinylcholine and intubation. Br J Anaesth. 2008 Apr;100(4):485-9. doi: 10.1093/bja/aen020. Epub 2008 Feb 19.</citation>
    <PMID>18285392</PMID>
  </results_reference>
  <results_reference>
    <citation>Peden CJ, Cloote AH, Stratford N, Prys-Roberts C. The effect of intravenous dexmedetomidine premedication on the dose requirement of propofol to induce loss of consciousness in patients receiving alfentanil. Anaesthesia. 2001 May;56(5):408-13.</citation>
    <PMID>11350323</PMID>
  </results_reference>
  <results_reference>
    <citation>Taittonen MT, Kirvelä OA, Aantaa R, Kanto JH. Effect of clonidine and dexmedetomidine premedication on perioperative oxygen consumption and haemodynamic state. Br J Anaesth. 1997 Apr;78(4):400-6.</citation>
    <PMID>9135361</PMID>
  </results_reference>
  <results_reference>
    <citation>Erkola O, Korttila K, Aho M, Haasio J, Aantaa R, Kallio A. Comparison of intramuscular dexmedetomidine and midazolam premedication for elective abdominal hysterectomy. Anesth Analg. 1994 Oct;79(4):646-53.</citation>
    <PMID>7943770</PMID>
  </results_reference>
  <results_reference>
    <citation>Virkkilä M, Ali-Melkkilä T, Kanto J, Turunen J, Scheinin H. Dexmedetomidine as intramuscular premedication for day-case cataract surgery. A comparative study of dexmedetomidine, midazolam and placebo. Anaesthesia. 1994 Oct;49(10):853-8.</citation>
    <PMID>7802178</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2013</study_first_submitted>
  <study_first_submitted_qc>September 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2013</study_first_posted>
  <last_update_submitted>September 7, 2013</last_update_submitted>
  <last_update_submitted_qc>September 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou First People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiangcai Ruan</investigator_full_name>
    <investigator_title>Professor, Deputy Director</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>intramuscular premedication</keyword>
  <keyword>bradycardiac</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

